Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Smoldering Multiple Myeloma 1Recurrence 1Prostatic Neoplasms 1Neoplasms, Plasma Cell 1Monoclonal Gammopathy of Undetermined Significance 1Leukemia, Myeloid, Acute 1Cytokine Release Syndrome 1Castleman Disease 1

Interventions

Lenalidomide 3PVX-410 vaccine 2siltuximab 1sargramostim 1poly ICLC 1dexamethasone acetate 1dexamethasone 21-phosphate 1citarinostat 1auricularum 1atezolizumab 1Receptors, Interleukin-6 1Monatide (IMS 3015) 1Interleukin 1 Receptor Antagonist Protein 1Emulsions 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Smoldering Multiple Myeloma × siltuximab × Clear all
NCT01219010 2015-01-19

A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma

Janssen Research & Development, LLC

Phase 1 Completed
30 enrolled
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡